Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09)
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The treatment of male breast cancer (MBC) has been extrapolated from female breast cancer (FBC) because of its rarity despite their different clinicopathologic characteristics. We aimed to investigate the distribution of intrinsic subtypes based on immunohistochemistry, their clinical impact, and treatment pattern in clinical practice through a multicenter study in Korea.Materials and Methods We retrospectively analyzed clinical data of 248 MBC patients from 18 institutions across the country from January 1995 to July 2016.Results The median age of MBC patients was 63 years (range, 25 to 102 years). Among 148 intrinsic subtype classified patients, 61 (41.2%), 44 (29.7%), 29 (19.5%), and 14 (9.5%) were luminal A, luminal B, human epidermal growth factor receptor 2, and triple-negative breast cancer, respectively. Luminal A subtype showed trends for superior survival compared to other subtypes. Most hormone receptor-positive patients (166 patients, 82.6%) received adjuvant endocrine treatment. Five-year completion of adjuvant endocrine treatment was associated with superior disease-free survival (DFS) in patients classified with an intrinsic subtype (hazard ratio [HR], 0.15; 95% confidence interval [CI], 0.04 to 0.49; p=0.002) and in all patients (HR, 0.16; 95% CI, 0.05 to 0.54; p=0.003).Conclusion Distribution of subtypes of MBC was similar to FBC and luminal type A was most common. Overall survival tended to be improved for luminal A subtype, although there was no statistical significance. Completion of adjuvant endocrine treatment was associated with prolonged DFS in intrinsic subtype classified patients. MBC patients tended to receive less treatment. MBC patients should receive standard treatment according to guidelines as FBC patients.
Abstract
Purpose The treatment of male breast cancer (MBC) has been extrapolated from female breast cancer (FBC) because of its rarity despite their different clinicopathologic characteristics. We aimed to investigate the distribution of intrinsic subtypes based on immunohistochemistry, their clinical impact, and treatment pattern in clinical practice through a multicenter study in Korea.Materials and Methods We retrospectively analyzed clinical data of 248 MBC patients from 18 institutions across the country from January 1995 to July 2016.Results The median age of MBC patients was 63 years (range, 25 to 102 years). Among 148 intrinsic subtype classified patients, 61 (41.2%), 44 (29.7%), 29 (19.5%), and 14 (9.5%) were luminal A, luminal B, human epidermal growth factor receptor 2, and triple-negative breast cancer, respectively. Luminal A subtype showed trends for superior survival compared to other subtypes. Most hormone receptor-positive patients (166 patients, 82.6%) received adjuvant endocrine treatment. Five-year completion of adjuvant endocrine treatment was associated with superior disease-free survival (DFS) in patients classified with an intrinsic subtype (hazard ratio [HR], 0.15; 95% confidence interval [CI], 0.04 to 0.49; p=0.002) and in all patients (HR, 0.16; 95% CI, 0.05 to 0.54; p=0.003).Conclusion Distribution of subtypes of MBC was similar to FBC and luminal type A was most common. Overall survival tended to be improved for luminal A subtype, although there was no statistical significance. Completion of adjuvant endocrine treatment was associated with prolonged DFS in intrinsic subtype classified patients. MBC patients tended to receive less treatment. MBC patients should receive standard treatment according to guidelines as FBC patients.
참고문헌 (33)
- Siegel RL, "Cancer statistics, 2019", CA Cancer J Clin, 69, pp.7~34 (2019)
- 홍세리, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2018", Cancer Research and Treatment, 53(2), pp.301~315 (2021), 대한암학회[DOI]
- 이은경, "Comparing the Characteristics and Outcomes of Male and Female Breast Cancer Patients in Korea: Korea Central Cancer Registry", Cancer Research and Treatment, 52(3), pp.739~746 (2020), 대한암학회[DOI]
- Noone AM, "SEER cancer statistics review, 1975-2015", National Cancer Institute, ~ (2018)
- Abdelwahab Yousef AJ, "Male breast cancer : epidemiology and risk factors", Semin Oncol, 44, pp.267~272 (2017)
- Giordano SH, "Breast cancer in men", N Engl J Med, 378, pp.2311~2320 (2018)
- Basham VM, "BRCA1 and BRCA2 mutations in a population-based study of male breast cancer", Breast Cancer Res, 4, pp.R2~ (2002)
- Ding YC, "Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States", Breast Cancer Res Treat, 126, pp.771~778 (2011)
- Friedman LS, "Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population", Am J Hum Genet, 60, pp.313~319 (1997)
- Ottini L, "BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer : a population-based study in Italy", Cancer Res, 63, pp.342~347 (2003)
- Cardoso F, "Characterization of male breast cancer : results of the EORTC 10085", TBCRC, NABCG International Male Breast Cancer Program, pp.Ann Oncol, 2018[DOI]
- Piscuoglio S, "The genomic landscape of male breast cancers", Clin Cancer Res, 22, pp.4045~4056 (2016)
- Callari M, "Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer", Breast Cancer Res Treat, 127, pp.601~610 (2011)
- Shaaban AM, "A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences", Breast Cancer Res Treat, 133, pp.949~958 (2012)
- Hassett MJ, "Management of male breast cancer : ASCO guideline", J Clin Oncol, 38, pp.1849~1863 (2020)
- Korde LA, "Multidisciplinary meeting on male breast cancer : summary and research recommendations", J Clin Oncol, 28, pp.2114~2122 (2010)
- 홍지형, "Clinical Features of Male Breast Cancer: Experiences from Seven Institutions Over 20 Years", Cancer Research and Treatment, 48(4), pp.1389~1398 (2016), 대한암학회
- Hammond ME, "American Society of Clinical Oncology", College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer(unabridged version), 2010, pp.134, e48~72
- Wolff AC, "American Society of Clinical Oncology", College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, 2007, pp.131, 18~43
- Wolff AC, "Recommendations for human epidermal growth factor receptor 2 testing in breast cancer : American Society of Clinical Oncology", College of American Pathologists clinical practice guideline update, 2013, pp.31, 3997~4013
- Gnant M, "St. Gallen", Vienna 2015 : a brief summary of the consensus discussion, 2015, pp.10, 124~130
- Amin MB, "AJCC cancer staging manual" (2010), Springer
- Korean Breast Cancer Society, "Breast Cancer Facts and Figures 2020", Korean Breast Cancer Society, ~ (2020)
- Baselga J, "Everolimus in postmenopausal hormonereceptor-positive advanced breast cancer", N Engl J Med, 366, pp.520~529 (2012)
- Sarmiento S, "Male breast cancer : a closer look at patient and tumor characteristics and factors that affect survival using the National Cancer Database", Breast Cancer Res Treat, 180, pp.471~479 (2020)
- Yadav S, "Male breast cancer in the United States : treatment patterns and prognostic factors in the 21st century", Cancer, 126, pp.26~36 (2020)
- Miao H, "Incidence and outcome of male breast cancer : an international population-based study", J Clin Oncol, 29, pp.4381~4386 (2011)
- Johansson I, "The landscape of candidate driver genes differs between male and female breast cancer", PLoS One, 8, pp.e78299~ (2013)
- Oke O, "Adjuvant tamoxifen adherence in men with early-stage breast cancer", Cancer, 128, pp.59~64 (2022)
- Gnerlich JL, "Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration", Ann Surg Oncol, 18, pp.1837~1844 (2011)
- Marchal F, "Men with breast cancer have same disease-specific and event-free survival as women", Ann Surg Oncol, 16, pp.972~978 (2009)
- Grenader T, "The 21-gene recurrence score assay(Oncotype DX)in estrogen receptor-positive male breast cancer : experience in an Israeli cohort", Oncology, 87, pp.1~6 (2014)
- Massarweh SA, "Molecular characterization and mortality from breast cancer in men", J Clin Oncol, 36, pp.1396~1404 (2018)